HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mamoru Hyodo Selected Research

Neoplasms (Cancer)

1/2022Combined nano cancer immunotherapy based on immune status in a tumor microenvironment.
1/2021STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
3/2016A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells.
10/2015Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma.
7/2015Multifunctional Envelope-Type Nano Device: Evolution from Nonselective to Active Targeting System.
8/2014Identification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand.
8/2014An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.
6/2014A new adjuvant delivery system 'cyclic di-GMP/YSK05 liposome' for cancer immunotherapy.
1/2014RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
1/2014Construction of an aptamer modified liposomal system targeted to tumor endothelial cells.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mamoru Hyodo Research Topics

Disease

15Neoplasms (Cancer)
01/2022 - 04/2005
8Infections
03/2016 - 03/2005
6Bites and Stings (Sting)
01/2021 - 02/2011
4Obesity
03/2014 - 10/2012
4Body Weight (Weight, Body)
10/2013 - 10/2012
2Melanoma (Melanoma, Malignant)
01/2021 - 10/2015
2Neoplasm Metastasis (Metastasis)
01/2021 - 10/2015
2Reperfusion Injury
12/2015 - 09/2015
2Renal Cell Carcinoma (Grawitz Tumor)
08/2014 - 01/2012
2Bacterial Infections (Bacterial Infection)
02/2011 - 08/2008
2Staphylococcal Infections
07/2009 - 02/2007
2Persistent Infection
01/2009 - 03/2005
2Mastitis
08/2005 - 03/2005
1Dehydration (Water Stress)
09/2021
1Shock
01/2021
1Lymphoma (Lymphomas)
03/2016
1Metabolic Diseases (Metabolic Disease)
03/2014
1Type 2 Diabetes Mellitus (MODY)
03/2014
1Disease Progression
03/2014
1Overweight
03/2014
1Whooping Cough (Pertussis)
01/2014
1Respiratory Tract Infections (Respiratory Tract Infection)
01/2014
1Metabolic Syndrome (Dysmetabolic Syndrome X)
10/2013
1Anaplasmosis
02/2009
1Chronic Disease (Chronic Diseases)
01/2009
1Pneumococcal Infections
08/2008
1Communicable Diseases (Infectious Diseases)
08/2008
1Pneumonia (Pneumonitis)
10/2007
1Bacterial Pneumonia
10/2007
1Neuroblastoma
04/2005
1Colonic Neoplasms (Colon Cancer)
04/2005

Drug/Important Bio-Agent (IBA)

12bis(3',5')-cyclic diguanylic acidIBA
10/2015 - 03/2005
7LigandsIBA
01/2021 - 01/2012
7Small Interfering RNA (siRNA)IBA
03/2016 - 01/2012
6Proteins (Proteins, Gene)FDA Link
01/2021 - 01/2009
5InterferonsIBA
01/2021 - 02/2011
4YSK05IBA
10/2015 - 06/2013
4Peptides (Polypeptides)IBA
10/2013 - 01/2012
4Pharmaceutical PreparationsIBA
06/2013 - 04/2005
3LipidsIBA
10/2015 - 06/2013
3Liposomes (Liposome)IBA
10/2015 - 06/2014
3Interferon Type IIBA
10/2015 - 02/2011
3Nucleotide AptamersIBA
08/2014 - 01/2012
3Phosphotransferases (Kinase)IBA
06/2014 - 01/2009
3DNA (Deoxyribonucleic Acid)IBA
05/2013 - 02/2011
3Vaccine AdjuvantsIBA
07/2009 - 10/2007
2Lipid NanoparticlesIBA
01/2022 - 01/2021
2Biomarkers (Surrogate Marker)IBA
08/2014 - 01/2012
2LeptinIBA
10/2013 - 03/2013
2NucleotidesIBA
09/2011 - 02/2011
2Immunologic Factors (Immunomodulators)IBA
08/2008 - 10/2007
2GpGpIBA
08/2005 - 04/2005
2Anti-Infective Agents (Microbicides)IBA
04/2005 - 03/2005
1AcidsIBA
09/2021
1Silicon Dioxide (Silica)FDA LinkGeneric
09/2021
1HydrogenIBA
09/2021
1pristane (pristan)IBA
09/2021
1allyl alcohol (allylic alcohol)IBA
09/2021
1SaltsIBA
01/2021
1Immune Checkpoint InhibitorsIBA
01/2021
1CytokinesIBA
03/2016
1SphingosineIBA
12/2015
1Hyaluronic Acid (Hyaluronan)IBA
12/2015
1Reactive Oxygen Species (Oxygen Radicals)IBA
09/2015
1coenzyme Q10 (CoQ10)IBA
09/2015
1APTIBA
08/2014
1Troponin T (Troponin T1)IBA
08/2014
1AntigensIBA
06/2014
1Adenosine Triphosphate (ATP)IBA
06/2014
1RNA Helicases (RNA Helicase)IBA
06/2014
1Blood Glucose (Blood Sugar)IBA
03/2014
1EnzymesIBA
03/2014
1AcyltransferasesIBA
03/2014
1Triglycerides (Triacylglycerol)IBA
03/2014
1MonoglyceridesIBA
03/2014
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2014
1ProhibitinsIBA
10/2013
1CKGGRAKDC-GG-D(KLAKLAK)2IBA
10/2013
1Messenger RNA (mRNA)IBA
06/2013
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
06/2013
1cyclic guanosine monophosphate-adenosine monophosphateIBA
05/2013
1Anti-Obesity Agents (Antiobesity Drugs)IBA
03/2013
1Cytochromes c (Cytochrome c)IBA
03/2013
1Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
11/2012
1Membrane Proteins (Integral Membrane Proteins)IBA
01/2012
1Nucleic AcidsIBA
09/2011
1RNA (Ribonucleic Acid)IBA
02/2011
1cyclic diadenosine phosphateIBA
02/2011
1Ethylnitrosourea (N-Ethyl-N-nitrosourea)IBA
02/2011
1diguanylate cyclaseIBA
02/2009
1Histidine KinaseIBA
02/2009
1N,N'- dipyridoxylethylenediamine- N,N'- diacetic acid (PLED)IBA
02/2009
1Virulence Factors (Pathogenicity Factors)IBA
01/2009
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
04/2005
1Epidermal Growth Factor (EGF)IBA
04/2005
1Acetylcholine (Acetylcholine Chloride)FDA Link
04/2005

Therapy/Procedure

6Therapeutics
01/2022 - 10/2013
5Immunotherapy
01/2022 - 06/2014
1Intravenous Administration
10/2015
1Injections
01/2014